Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

5    Teva    $15.1B    down 5%
Global revenue: $18.3B (12th); up 13.7%

R&D spend: $1.1B (18th), up 18.3%; 6% of rev.

Top brands: Copaxone ($3.0B); Provigil ($1.1B), ProAir HFA ($953M), ­budesonide ($856M)

Planned launches: Custirsen (onc.); neugranin (onc.); Revascor (CV)

Promotional spend: $257M (16th); 1.7% of rev.

Patent expirations: Copaxone (2014), Treanda (2015)

This multi-billion dollar company is proof that generics can be big ­business. Although Teva saw its North America earnings power shrink to 48% of its sales in 2011 from 62% in 2010, the Israeli company balanced things out, increasing sales to 31% in Europe, up from 24% in 2010, and hauled in 21% of its take from international sales, compared with 14% the year before. Although the company remains solidly in the unbranded drug space, its $6.8-billion purchase last year of Cephalon and its CNS portfolio means more exposure to the brand side of the patent-protection wars, as CNS drugs Provigil, Copaxone and Treanda burn through their exclusivity periods. Teva dealt Par the right to sell an authorized generic of Provigil, meaning Teva earns from both ends of the patent spectrum. The company says it has 177 product registrations awaiting FDA approval—120 of these are patent challenges for first-to-market generic rights.

Back to first page

Page 5 of 21
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.